<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01068652</url>
  </required_header>
  <id_info>
    <org_study_id>INS-3782</org_study_id>
    <secondary_id>U1111-1112-6407</secondary_id>
    <nct_id>NCT01068652</nct_id>
  </id_info>
  <brief_title>Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs</brief_title>
  <official_title>Effect of 50-week Treatment With Stepwise Insulin Intensification of Basal-bolus Insulin Analogues (Insulin Detemir and Aspart) or Biphasic Insulin Aspart 30 (NovoMix 30) All in Combination With Fixed Dose of Metformin on Glycaemic Control (Measured as HbA1c) in Subjects With Type 2 Diabetes. Open Labelled, Randomized, Two-arm, Parallel Group, Multi-centre, Multi-national Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Africa. The aim of this clinical trial is to investigate the
      effect of 50 weeks of treatment with different intensified insulin administrations (all in
      combination with a fixed dose of metformin) on blood sugar control in subjects with type 2
      diabetes inadequately controlled by oral anti-diabetic drugs (OADs).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycosylated Haemoglobin (HbA1c)</measure>
    <time_frame>Week 50</time_frame>
    <description>Estimated mean difference in HbA1c after 50 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Glycosylated Haemoglobin (HbA1c) After 14 Weeks of Treatment</measure>
    <time_frame>Week 0, Week 14</time_frame>
    <description>Observed mean change from baseline in HbA1c at Week 14 (visit 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Observed mean change in from baseline in HbA1c at Week 26 (visit 18)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycosylated Haemoglobin (HbA1c) After 38 Weeks of Treatment</measure>
    <time_frame>Week 0, Week 38</time_frame>
    <description>Observed mean change from baseline in HbA1c at Week 38 (visit 25)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycosylated Haemoglobin (HbA1c) at Week 50</measure>
    <time_frame>Week 0, Week 50</time_frame>
    <description>Observed mean change from baseline in HbA1c at Week 50 (visit 32)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 14 Weeks of Treatment</measure>
    <time_frame>Week 14</time_frame>
    <description>Number of subjects achieving HbA1c below 7.0% after 14 weeks of treatment (visit 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 26 Weeks of Treatment</measure>
    <time_frame>Week 26</time_frame>
    <description>Number of subjects achieving HbA1c below 7.0% after 26 weeks of treatment (visit 18)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 38 Weeks of Treatment</measure>
    <time_frame>Week 38</time_frame>
    <description>Number of subjects achieving HbA1c below 7.0% after 38 weeks of treatment (visit 25)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 50 Weeks of Treatment</measure>
    <time_frame>Week 50</time_frame>
    <description>Number of subjects achieving HbA1c below 7.0% after 50 weeks of treatment (visit 32)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Prandial Plasma Glucose (PG) Increment After 14 Weeks of Treatment</measure>
    <time_frame>Week 14</time_frame>
    <description>Observed overall mean of PG increment after 14 weeks of treatment (Visit 11). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Prandial Plasma Glucose (PG) Increment After 26 Weeks of Treatment</measure>
    <time_frame>Week 26</time_frame>
    <description>Observed overall mean of PG increment after 26 weeks of treatment (visit 18). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Prandial Plasma Glucose (PG) Increment After 38 Weeks of Treatment</measure>
    <time_frame>Week 38</time_frame>
    <description>Observed overall mean of PG increment after 38 weeks of treatment (visit 25). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Prandial Plasma Glucose (PG) Increment After 50 Weeks of Treatment</measure>
    <time_frame>Week 50</time_frame>
    <description>Observed overall mean of PG increment after 50 weeks of treatment (visit 32). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of 8-point Plasma Glucose (PG) Profile After 14 Weeks of Treatment</measure>
    <time_frame>Week 14</time_frame>
    <description>Observed overall mean of 8-point PG profile after 14 weeks of treatment (visit 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of 8-point Plasma Glucose (PG) Profile After 26 Weeks of Treatment</measure>
    <time_frame>Week 26</time_frame>
    <description>Observed overall mean of 8-point PG profile after 26 weeks of treatment (visit 18)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of 8-point Plasma Glucose (PG) Profile After 38 Weeks of Treatment</measure>
    <time_frame>Week 38</time_frame>
    <description>Observed overall mean of 8-point PG profile after 38 weeks of treatment (visit 25)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of 8-point Plasma Glucose (PG) Profile After 50 Weeks of Treatment</measure>
    <time_frame>Week 50</time_frame>
    <description>Observed overall mean of 8-point PG profile after 50 weeks of treatment (visit 32)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">403</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Detemir + Met</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIAsp 30 + Met</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin detemir</intervention_name>
    <description>Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin).</description>
    <arm_group_label>Detemir + Met</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin aspart</intervention_name>
    <description>Pending evaluation of HbA1c every 3 months, insulin aspart was added to the insulin detemir treatment (up to three does daily, injected s.c. (under the skin)</description>
    <arm_group_label>Detemir + Met</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 30</intervention_name>
    <description>Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin). Pending evaluation of HbA1c every 3 months, the dose will intensified up to 3 doses daily</description>
    <arm_group_label>BIAsp 30 + Met</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>1000-2000 mg/day in combination with insulin treatment</description>
    <arm_group_label>Detemir + Met</arm_group_label>
    <arm_group_label>BIAsp 30 + Met</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities. (Trial-related
             activities are any procedure that would not have been performed during normal
             management of the subject)

          -  Diagnosed type 2 diabetes (WHO 1999 criteria)

          -  Currently treated with suboptimal daily dose of OADs (mono or combination therapy) for
             at least 6 months

          -  Male or female age at least 18 years old

          -  HbA1c at least 7.0 % and maximum 11.0% for subjects treated with metformin
             mono-therapy, or maximum 10% for subjects treated with OAD combination therapy

          -  BMI maximum 40 kg/m^2

          -  Able and willing to perform self-monitoring of plasma glucose according to the
             protocol and to keep a diary

          -  Able and willing to be treated with up to 4 insulin injections per day

        Exclusion Criteria:

          -  Known or suspected allergy to trial product(s) or related products

          -  Previous participation in this trial. Participation is defined as randomisation

          -  Females of childbearing potential who are pregnant, breast-feeding or intend to become
             pregnant or are not using adequate contraceptive methods (adequate contraceptive
             measures as required by local law or practice)

          -  Participated in another clinical trial and received an investigational drug within the
             last weeks prior to the present trial

          -  Impaired hepatic function defined as alanine aminotransferase (ALT) or alkaline
             phosphatase (ALP) at least 2.5 times upper referenced limit

          -  Impaired renal function defined as serum-creatinine at least 1.3 mg/dL (at least 115
             mmol/L) for males and at least 1.2 mg/dL (at least 106 mmol/L) for females

          -  Subject has a clinically significant, active (or over the past 12 months)
             cardiovascular history (including a history of myocardial infarction (MI), arrhythmias
             or conduction delays on ECG, unstable angina, or decompensated heart failure (New York
             Heart Association class III and IV)

          -  Severe uncontrolled treated or untreated hypertension (sitting systolic blood pressure
             at least 180 mmHg or sitting diastolic blood pressure at least 100 mmHg)

          -  Proliferative retinopathy or macular oedema requiring acute treatment

          -  Metformin contraindications according to the package insert

          -  Current treatment with systemic corticosteroids

          -  Subject has a history of any illness that, in the opinion of the investigator, might
             confound the results of the study or pose additional risk in administering study drug
             to the subject

          -  Current addiction to alcohol or other addictive substances as determined by the
             Investigator

          -  Mental incapacity, unwillingness or language barrier precluding adequate understanding
             or cooperation in the study or use of the glucose monitor

          -  History of hypoglycaemic unawareness and/or two or more severe hypoglycaemic episodes
             in the past year as judged by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ain Témouchent</city>
        <zip>46000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Alger</city>
        <zip>16000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Algiers</city>
        <zip>16000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Constantine</city>
        <zip>25000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oran</city>
        <zip>31000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Setif</city>
        <zip>19000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sidi Bel Abbes</city>
        <zip>22000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Casablanca</city>
        <zip>20000</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <zip>6014</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1812</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0083</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vaderbijlpark</city>
        <state>Gauteng</state>
        <zip>1900</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4170</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4450</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kimberly</city>
        <state>Northern Cape</state>
        <zip>8301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7945</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sandton</city>
        <zip>2146</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tunisia</city>
        <zip>1053</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Egypt</country>
    <country>Morocco</country>
    <country>South Africa</country>
    <country>Tunisia</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2010</study_first_submitted>
  <study_first_submitted_qc>February 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2010</study_first_posted>
  <results_first_submitted>February 26, 2013</results_first_submitted>
  <results_first_submitted_qc>February 26, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 8, 2013</results_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at 23 sites in 4 countries: Egypt (1), Algeria (9), Tunisia (4) and South Africa (9). The trial consisted of two weeks of screening, three weeks of run-in, and 50 weeks of treatment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Detemir + Met</title>
          <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
        </group>
        <group group_id="P2">
          <title>BIAsp 30 + Met</title>
          <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="188"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient was not eligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Detemir + Met</title>
          <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
        </group>
        <group group_id="B2">
          <title>BIAsp 30 + Met</title>
          <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
            <count group_id="B2" value="203"/>
            <count group_id="B3" value="403"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.0" spread="9.0"/>
                    <measurement group_id="B2" value="52.6" spread="10.1"/>
                    <measurement group_id="B3" value="52.8" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="241"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated haemoglobin (HbA1c)</title>
          <units>percentage of glycosylated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.6" spread="1.1"/>
                    <measurement group_id="B2" value="8.7" spread="1.1"/>
                    <measurement group_id="B3" value="8.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glycosylated Haemoglobin (HbA1c)</title>
        <description>Estimated mean difference in HbA1c after 50 weeks of treatment</description>
        <time_frame>Week 50</time_frame>
        <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 20 subjects, HbA1c values were missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Glycosylated Haemoglobin (HbA1c)</title>
          <description>Estimated mean difference in HbA1c after 50 weeks of treatment</description>
          <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 20 subjects, HbA1c values were missing.</population>
          <units>percentage of glycosylated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.34" spread="0.13"/>
                    <measurement group_id="O2" value="7.23" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To investigate the effect of different treatments, an analysis of covariance (ANCOVA) model was used to analyse HbA1c at week 50 with treatment group (2 categories: insulin detemir and aspart; BIAsp 30), country and pre-trial OAD(s) treatment (one OAD vs. more OADs) as factors and HbA1c at baseline (week 0) as a covariate. The treatment difference was estimated and a 95% confidence interval (CI) for the difference was calculated.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The treatment comparison was based on a non-inferiority criterion and the following hypotheses were tested: H0: μDetemir - μBIAsp 30 ≥0.4% against the alternative hypothesis (Detemir non-inferior to BIAsp 30) HA: μDetemir - μBIAsp 30 &lt;0.4% where μBIAsp 30 and μDetemir are the mean HbA1c after 50 weeks of treatment with the two treatment regimens.</non_inferiority_desc>
            <p_value>0.3406</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glycosylated Haemoglobin (HbA1c) After 14 Weeks of Treatment</title>
        <description>Observed mean change from baseline in HbA1c at Week 14 (visit 11)</description>
        <time_frame>Week 0, Week 14</time_frame>
        <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 20 subjects, values for change in HbA1c were missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycosylated Haemoglobin (HbA1c) After 14 Weeks of Treatment</title>
          <description>Observed mean change from baseline in HbA1c at Week 14 (visit 11)</description>
          <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 20 subjects, values for change in HbA1c were missing.</population>
          <units>percentage of glycosylated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="1.16"/>
                    <measurement group_id="O2" value="-0.64" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment</title>
        <description>Observed mean change in from baseline in HbA1c at Week 26 (visit 18)</description>
        <time_frame>Week 0, Week 26</time_frame>
        <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 20 subjects, values for change in HbA1c were missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment</title>
          <description>Observed mean change in from baseline in HbA1c at Week 26 (visit 18)</description>
          <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 20 subjects, values for change in HbA1c were missing.</population>
          <units>percentage of glycosylated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" spread="1.05"/>
                    <measurement group_id="O2" value="-1.30" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glycosylated Haemoglobin (HbA1c) After 38 Weeks of Treatment</title>
        <description>Observed mean change from baseline in HbA1c at Week 38 (visit 25)</description>
        <time_frame>Week 0, Week 38</time_frame>
        <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 20 subjects, values for change in HbA1c were missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycosylated Haemoglobin (HbA1c) After 38 Weeks of Treatment</title>
          <description>Observed mean change from baseline in HbA1c at Week 38 (visit 25)</description>
          <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 20 subjects, values for change in HbA1c were missing.</population>
          <units>percentage of glycosylated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="1.16"/>
                    <measurement group_id="O2" value="-1.56" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glycosylated Haemoglobin (HbA1c) at Week 50</title>
        <description>Observed mean change from baseline in HbA1c at Week 50 (visit 32)</description>
        <time_frame>Week 0, Week 50</time_frame>
        <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 20 subjects, values for change in HbA1c were missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycosylated Haemoglobin (HbA1c) at Week 50</title>
          <description>Observed mean change from baseline in HbA1c at Week 50 (visit 32)</description>
          <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 20 subjects, values for change in HbA1c were missing.</population>
          <units>percentage of glycosylated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="1.33"/>
                    <measurement group_id="O2" value="-1.34" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 14 Weeks of Treatment</title>
        <description>Number of subjects achieving HbA1c below 7.0% after 14 weeks of treatment (visit 11)</description>
        <time_frame>Week 14</time_frame>
        <population>Full Analysis Set (FAS) includes all randomised subjects. For 20 subjects, values were missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 14 Weeks of Treatment</title>
          <description>Number of subjects achieving HbA1c below 7.0% after 14 weeks of treatment (visit 11)</description>
          <population>Full Analysis Set (FAS) includes all randomised subjects. For 20 subjects, values were missing.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 26 Weeks of Treatment</title>
        <description>Number of subjects achieving HbA1c below 7.0% after 26 weeks of treatment (visit 18)</description>
        <time_frame>Week 26</time_frame>
        <population>Full Analysis Set (FAS) includes all randomised subjects. For 29 subjects, values were missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 26 Weeks of Treatment</title>
          <description>Number of subjects achieving HbA1c below 7.0% after 26 weeks of treatment (visit 18)</description>
          <population>Full Analysis Set (FAS) includes all randomised subjects. For 29 subjects, values were missing.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 38 Weeks of Treatment</title>
        <description>Number of subjects achieving HbA1c below 7.0% after 38 weeks of treatment (visit 25)</description>
        <time_frame>Week 38</time_frame>
        <population>Full Analysis Set (FAS) includes all randomised subjects. For 31 subjects, values were missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 38 Weeks of Treatment</title>
          <description>Number of subjects achieving HbA1c below 7.0% after 38 weeks of treatment (visit 25)</description>
          <population>Full Analysis Set (FAS) includes all randomised subjects. For 31 subjects, values were missing.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 50 Weeks of Treatment</title>
        <description>Number of subjects achieving HbA1c below 7.0% after 50 weeks of treatment (visit 32)</description>
        <time_frame>Week 50</time_frame>
        <population>Full Analysis Set (FAS) includes all randomised subjects. For 35 subjects, values were missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 50 Weeks of Treatment</title>
          <description>Number of subjects achieving HbA1c below 7.0% after 50 weeks of treatment (visit 32)</description>
          <population>Full Analysis Set (FAS) includes all randomised subjects. For 35 subjects, values were missing.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of Prandial Plasma Glucose (PG) Increment After 14 Weeks of Treatment</title>
        <description>Observed overall mean of PG increment after 14 weeks of treatment (Visit 11). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast – Pre Breakfast), (Post Lunch – Pre Lunch) and (Post Dinner - Pre Dinner)}</description>
        <time_frame>Week 14</time_frame>
        <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 28 subjects, PG (mg/dL) increment values were missing at all evaluations.</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of Prandial Plasma Glucose (PG) Increment After 14 Weeks of Treatment</title>
          <description>Observed overall mean of PG increment after 14 weeks of treatment (Visit 11). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast – Pre Breakfast), (Post Lunch – Pre Lunch) and (Post Dinner - Pre Dinner)}</description>
          <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 28 subjects, PG (mg/dL) increment values were missing at all evaluations.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.19" spread="33.64"/>
                    <measurement group_id="O2" value="32.61" spread="31.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of Prandial Plasma Glucose (PG) Increment After 26 Weeks of Treatment</title>
        <description>Observed overall mean of PG increment after 26 weeks of treatment (visit 18). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast – Pre Breakfast), (Post Lunch – Pre Lunch) and (Post Dinner - Pre Dinner)}</description>
        <time_frame>Week 26</time_frame>
        <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 19 subjects, PG (mg/dL) increment values were missing at all evaluations.</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of Prandial Plasma Glucose (PG) Increment After 26 Weeks of Treatment</title>
          <description>Observed overall mean of PG increment after 26 weeks of treatment (visit 18). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast – Pre Breakfast), (Post Lunch – Pre Lunch) and (Post Dinner - Pre Dinner)}</description>
          <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 19 subjects, PG (mg/dL) increment values were missing at all evaluations.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.95" spread="30.25"/>
                    <measurement group_id="O2" value="31.71" spread="27.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of Prandial Plasma Glucose (PG) Increment After 38 Weeks of Treatment</title>
        <description>Observed overall mean of PG increment after 38 weeks of treatment (visit 25). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast – Pre Breakfast), (Post Lunch – Pre Lunch) and (Post Dinner - Pre Dinner)}.</description>
        <time_frame>Week 38</time_frame>
        <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 19 subjects, PG (mg/dL) increment values were missing at all evaluations.</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of Prandial Plasma Glucose (PG) Increment After 38 Weeks of Treatment</title>
          <description>Observed overall mean of PG increment after 38 weeks of treatment (visit 25). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast – Pre Breakfast), (Post Lunch – Pre Lunch) and (Post Dinner - Pre Dinner)}.</description>
          <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 19 subjects, PG (mg/dL) increment values were missing at all evaluations.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.44" spread="27.95"/>
                    <measurement group_id="O2" value="28.32" spread="30.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of Prandial Plasma Glucose (PG) Increment After 50 Weeks of Treatment</title>
        <description>Observed overall mean of PG increment after 50 weeks of treatment (visit 32). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast – Pre Breakfast), (Post Lunch – Pre Lunch) and (Post Dinner - Pre Dinner)}.</description>
        <time_frame>Week 50</time_frame>
        <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 19 subjects, PG (mg/dL) increment values were missing at all evaluations.</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of Prandial Plasma Glucose (PG) Increment After 50 Weeks of Treatment</title>
          <description>Observed overall mean of PG increment after 50 weeks of treatment (visit 32). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast – Pre Breakfast), (Post Lunch – Pre Lunch) and (Post Dinner - Pre Dinner)}.</description>
          <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 19 subjects, PG (mg/dL) increment values were missing at all evaluations.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.45" spread="25.50"/>
                    <measurement group_id="O2" value="23.66" spread="28.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of 8-point Plasma Glucose (PG) Profile After 14 Weeks of Treatment</title>
        <description>Observed overall mean of 8-point PG profile after 14 weeks of treatment (visit 11)</description>
        <time_frame>Week 14</time_frame>
        <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of 8-point Plasma Glucose (PG) Profile After 14 Weeks of Treatment</title>
          <description>Observed overall mean of 8-point PG profile after 14 weeks of treatment (visit 11)</description>
          <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Breakfast (n=193, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.44" spread="42.86"/>
                    <measurement group_id="O2" value="128.31" spread="33.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min After Breakfast (n=187, 184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.89" spread="54.42"/>
                    <measurement group_id="O2" value="176.31" spread="44.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Lunch (n=192, 193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.61" spread="53.43"/>
                    <measurement group_id="O2" value="156.12" spread="51.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min After Lunch (n=186, 185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199.40" spread="64.38"/>
                    <measurement group_id="O2" value="199.75" spread="59.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Dinner (n=191, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.69" spread="54.91"/>
                    <measurement group_id="O2" value="168.09" spread="59.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min After Dinner (n=183, 185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212.23" spread="61.45"/>
                    <measurement group_id="O2" value="173.95" spread="54.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bedtime (n=187, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.15" spread="60.83"/>
                    <measurement group_id="O2" value="156.65" spread="50.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 2 AM - 3 AM (n=172, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.69" spread="50.06"/>
                    <measurement group_id="O2" value="139.93" spread="43.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of 8-point Plasma Glucose (PG) Profile After 26 Weeks of Treatment</title>
        <description>Observed overall mean of 8-point PG profile after 26 weeks of treatment (visit 18)</description>
        <time_frame>Week 26</time_frame>
        <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of 8-point Plasma Glucose (PG) Profile After 26 Weeks of Treatment</title>
          <description>Observed overall mean of 8-point PG profile after 26 weeks of treatment (visit 18)</description>
          <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Breakfast (n=193, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.57" spread="34.40"/>
                    <measurement group_id="O2" value="115.79" spread="27.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min After Breakfast (n=191, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.52" spread="50.02"/>
                    <measurement group_id="O2" value="153.85" spread="42.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Lunch (n=193, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.97" spread="49.96"/>
                    <measurement group_id="O2" value="131.27" spread="42.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min After Lunch (n=191, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.00" spread="57.15"/>
                    <measurement group_id="O2" value="178.92" spread="51.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Dinner (n=192, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.58" spread="48.90"/>
                    <measurement group_id="O2" value="143.29" spread="45.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min After Dinner (n=188, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.21" spread="57.34"/>
                    <measurement group_id="O2" value="152.44" spread="45.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bedtime (n=190, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.70" spread="63.68"/>
                    <measurement group_id="O2" value="140.39" spread="42.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 2 AM - 3 AM (n=181, 187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.59" spread="47.54"/>
                    <measurement group_id="O2" value="123.29" spread="35.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of 8-point Plasma Glucose (PG) Profile After 38 Weeks of Treatment</title>
        <description>Observed overall mean of 8-point PG profile after 38 weeks of treatment (visit 25)</description>
        <time_frame>Week 38</time_frame>
        <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of 8-point Plasma Glucose (PG) Profile After 38 Weeks of Treatment</title>
          <description>Observed overall mean of 8-point PG profile after 38 weeks of treatment (visit 25)</description>
          <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Breakfast (n=193, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.14" spread="30.64"/>
                    <measurement group_id="O2" value="110.86" spread="27.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min After Breakfast (n=191, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.70" spread="44.11"/>
                    <measurement group_id="O2" value="139.38" spread="42.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Lunch (n=193, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.63" spread="42.17"/>
                    <measurement group_id="O2" value="118.30" spread="40.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min After Lunch (n=191, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.91" spread="51.38"/>
                    <measurement group_id="O2" value="158.45" spread="47.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Dinner (n=193, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.26" spread="41.90"/>
                    <measurement group_id="O2" value="129.10" spread="43.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min After Dinner (n=192,192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.47" spread="49.09"/>
                    <measurement group_id="O2" value="142.82" spread="50.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bedtime (n=193, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.37" spread="51.58"/>
                    <measurement group_id="O2" value="132.45" spread="43.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 2 AM - 3 AM (n=187, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.57" spread="42.11"/>
                    <measurement group_id="O2" value="117.42" spread="35.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of 8-point Plasma Glucose (PG) Profile After 50 Weeks of Treatment</title>
        <description>Observed overall mean of 8-point PG profile after 50 weeks of treatment (visit 32)</description>
        <time_frame>Week 50</time_frame>
        <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir + Met</title>
            <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
          <group group_id="O2">
            <title>BIAsp 30 + Met</title>
            <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of 8-point Plasma Glucose (PG) Profile After 50 Weeks of Treatment</title>
          <description>Observed overall mean of 8-point PG profile after 50 weeks of treatment (visit 32)</description>
          <population>Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Breakfast (n=193, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.78" spread="31.10"/>
                    <measurement group_id="O2" value="110.76" spread="22.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min After Breakfast (n=191, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.05" spread="40.98"/>
                    <measurement group_id="O2" value="132.45" spread="35.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Lunch (n=193, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.43" spread="37.62"/>
                    <measurement group_id="O2" value="115.02" spread="36.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min After Lunch (n=191, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.48" spread="49.03"/>
                    <measurement group_id="O2" value="149.90" spread="44.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Dinner (n=193, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.28" spread="40.63"/>
                    <measurement group_id="O2" value="126.76" spread="40.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min After Dinner (n=192, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.19" spread="49.24"/>
                    <measurement group_id="O2" value="138.08" spread="42.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bedtime (n=193, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.13" spread="51.18"/>
                    <measurement group_id="O2" value="130.10" spread="43.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 2 AM - 3 AM (n=187, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.60" spread="40.65"/>
                    <measurement group_id="O2" value="113.14" spread="35.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events were collected in a time frame of 0-50 weeks + 2 weeks follow-up</time_frame>
      <desc>Safety analysis set includes all subjects who received at least one dose of the investigational product or its comparator</desc>
      <group_list>
        <group group_id="E1">
          <title>Detemir + Met</title>
          <description>Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.</description>
        </group>
        <group group_id="E2">
          <title>BIAsp 30 + Met</title>
          <description>Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ECG signs of myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="200"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="200"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="200"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="200"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="200"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="200"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

